Recombinant poxviral vectors expressing both rabies and OX40 proteins, and vaccines made therefrom
AssigneeMerial Limited
InventorsTeshome Mebatsion, Jules Maarten Minke, Frederic David
Life of this patent
Estimating the term…
Abstract
The present invention provides vectors that contain and co-express in vivo or in vitro immunogenic polypeptides or antigens together with an OX40L polypeptide, which functions as a genetic adjuvant. Together, the immunogenic polypeptide and the OX40L polypeptide elicit an immune response in animal or human, which is greater than the immune response elicited by the immunogenic polypeptide alone. In a particular example, the invention provides vectors encoding a Rabies G immunogenic polypeptide and a canine OX40L genetic adjuvant, which vectors elicit strong immune responses in canine against rabies virus.
Claims16
A vaccine composition comprising or consisting essentially of:
- a) a recombinant poxviral vector comprising a polynucleotide comprising four Rabies G genes and one canine OX40L gene, each expressing in vivo in an animal host in need thereof;
- and
- b) a pharmaceutically or veterinarily acceptable vehicle, diluent or excipient;
- and
- wherein two of the Rabies G genes are classic genes and two of the Rabies G genes are codon-optimized genes;
- and
- wherein the vector comprises the sequence as set forth in SEQ ID NO:
- 23.
A recombinant poxviral vector comprising at least one polynucleotide encoding:
- (a) four copies of a Rabies G polypeptide;
- and
- (b) a canine OX40L polypeptide;
- wherein the polynucleotide comprises a gene encoding the OX40L polypeptide, inserted into the vector's C6 locus;
- and
- wherein the polynucleotide comprises genes encoding the Rabies G polypeptides, inserted into the vector's C3 loci and C5 loci;
- and wherein the vector comprises the sequence as set forth in SEQ ID NO:
- 23.
Dependencies are inferred from the claim text.